Editor's Choice
ASIC to take 'balanced' stance on super advertising ban rules
|The corporate regulator said it promises to take a "balanced" approach to enforcing new rules around any advertising of superannuation funds during the employee onboarding process, which take effect in a few weeks.
BlackRock expands active ETF range
|BlackRock is set to expand its Australian ETF range with the launch of the iShares World Equity High Income Complex ETF (ASX: WYNC), an actively managed strategy targeting investors seeking both income and broad global equity exposure.
T. Rowe Price names head of intermediary for Australia
|T. Rowe Price has appointed a head of intermediary for Australia, following a three-month absence in the role after Jonathan Ross' departure in March.
FEATURE | Aged care: The longevity dividend
It's not just Australia that is dealing with an aging population, in fact the World Health Organisation estimates by 2030, one in six people will be aged 60 years or over.
Products
Expert Feed
When geopolitics becomes a portfolio risk
Geopolitics is back - again - and Australian investors can no longer treat it as distant background noise.
Does association membership still matter?
With all the changes the advice sector has experienced in recent years, such as regulatory reform and increased education and professional standards ...
Digital assets and where they stand in 2026
So far in 2026 digital assets have captured the headlines largely for the wrong reasons, but that doesn't tell the full story.
Rethinking default design in a changing market environment
The evolution underway in the US DC system highlights the value of periodically reassessing default design assumptions.
Featured Profile
Brian Redican
CHIEF ECONOMIST
NEW SOUTH WALES TREASURY CORPORATION
NEW SOUTH WALES TREASURY CORPORATION
What makes an economist an economist? TCorp chief economist Brian Redican reflects on over three decades of navigating Australia's economic cycles. Riddhima Talwani writes.
Comparing to the pharmaceutical industries: We do not observe doctors being directly employed by Pharmaceutical companies. Any semblance of independence in medical advice would otherwise be irreparably damaged.
Why doesn't anyone look at the doctor & pharmaceuticals relationship of kickbacks on prescribing medicines?
The pharmaceutical industry is more corrupt than any industry.
Leave the planners alone, get the Cowboys but leave the majority of us who do an honest job alone.